Skip to main content

Table 1 Eligibility criteria of included studies

From: The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review


Women with HER2-positive breast cancer


Neoadjuvant or adjuvant treatment with subcutaneous trastuzumab


Neoadjuvant or adjuvant treatment with intravenous trastuzumab


• Efficacy (overall survival, event-free survival)

• Safety: overall risk of adverse events, serious adverse events, discontinuation because of adverse events

• Patients’ preferences

Study design

RCTs, systematic reviews, and meta-analyses

  1. HER human epidermal growth factor receptor, RCT randomized controlled trial